Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation.
Anthony P CarnicelliSana M Al-KhatibDenis XavierFrederik DalgaardPeter D MerrillDaniel M WojdylaBasil S LewisMichael HannaJohn H AlexanderRenato Deláscio LopesLars WallentinChristopher B GrangerPublished in: Heart (British Cardiac Society) (2020)
Premature permanent discontinuation of study drug in ARISTOTLE was common, less frequent in patients receiving apixaban than warfarin and was followed by high 30-day rates of death, thromboembolism and major bleeding. Initiatives are needed to reduce discontinuation of oral anticoagulation.